Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Eargo Inc is a medical devices business based in the US. Eargo shares (EAR) are listed on the NASDAQ and all prices are listed in US Dollars. Eargo employs 238 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Experienced Investors
Our top pick for
Large Accounts
| Latest market close | $7.57 |
|---|---|
| 52-week range | $6.20 - $76.75 |
| 50-day moving average | $14.13 |
| 200-day moving average | $32.28 |
| Wall St. target price | $9.93 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.65 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $7.57 from 2021-10-20
| 1 week (2021-10-15) | 5.14% |
|---|---|
| 1 month (2021-09-22) | -65.07% |
| 3 months (2021-07-22) | -78.10% |
| 6 months (2021-04-22) | -84.56% |
| 1 year (2020-10-21) | -78.09% |
|---|---|
| 2 years (2019-10-18) | N/A |
| 3 years (2018-10-18) | N/A |
| 5 years (2016-10-18) | N/A |
| Revenue TTM | $85.5 million |
|---|---|
| Gross profit TTM | $47.3 million |
| Return on assets TTM | -25.17% |
| Return on equity TTM | -70.11% |
| Profit margin | -63.71% |
| Book value | $4.49 |
| Market capitalisation | $282.7 million |
TTM: trailing 12 months
There are currently 1.7 million Eargo shares held short by investors – that's known as Eargo's "short interest". This figure is 33.9% down from 2.6 million last month.
There are a few different ways that this level of interest in shorting Eargo shares can be evaluated.
Eargo's "short interest ratio" (SIR) is the quantity of Eargo shares currently shorted divided by the average quantity of Eargo shares traded daily (recently around 4.3 million). Eargo's SIR currently stands at 0.4. In other words for every 100,000 Eargo shares traded daily on the market, roughly 400 shares are currently held short.
To gain some more context, you can compare Eargo's short interest ratio against those of similar companies.
However Eargo's short interest can also be evaluated against the total number of Eargo shares, or, against the total number of tradable Eargo shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Eargo's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Eargo shares in existence, roughly 40 shares are currently held short) or 0.0726% of the tradable shares (for every 100,000 tradable Eargo shares, roughly 73 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Eargo.
Find out more about how you can short Eargo stock.
We're not expecting Eargo to pay a dividend over the next 12 months.
Eargo, Inc. , a medical device company, develops and sells hearing aids to assist people with hearing loss in the United States. It sells its products through online stores. The company was formerly known as Aria Innovations, Inc. and changed its name to Eargo, Inc. in November 2014. Eargo, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
